Trajectories of medication adherence in patients with Bipolar Disorder along 2 years-follow-up.


Journal

Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073

Informations de publication

Date de publication:
01 03 2021
Historique:
received: 22 10 2020
revised: 23 12 2020
accepted: 26 12 2020
entrez: 19 2 2021
pubmed: 20 2 2021
medline: 27 4 2021
Statut: ppublish

Résumé

Bipolar disorder (BD) is a chronic and severe mental illness. It requires a non-discontinued pharmacological treatment to prevent mood recurrences but nonadherence to medication is frequent. To this date, medication adherence in BD has been mostly evaluated in cross-sectional studies and often considered as a stable trait. We aimed to study medication adherence using a prospective person-oriented approach. 1627 BD patients were followed on a 2 years period and assessed every 6 months. Medication adherence was evaluated at each visit with the Medication Adherence Rating Scale (MARS). A latent class mixed model (LCMM) was used to identify trajectory classes of adherence over time. Regression analyses and linear mixed model were used to search for predictors and covariables of the trajectories. Three distinct and robust trajectories of medication adherence have been identified: one that starts poorly and keeps deteriorating (4.8%), one that starts poorly but improves (9%) and one that starts well and keeps improving (86.2%). A good tolerance to psychotropic medications, low depressive symptoms, the absence of comorbid eating disorders and anticonvulsant medication were associated to a better prognosis of adherence. Along the follow-up, the lower were the depressive symptoms, the better was the medication adherence (p < .001) LIMITATIONS: The use of a single measure of medication adherence although it is a validated instrument and a possible positive selection bias that might limit the generalization of our findings. This study demonstrates that medication adherence in BD patients is a heterogeneous and potentially variable phenomenon.

Sections du résumé

BACKGROUND
Bipolar disorder (BD) is a chronic and severe mental illness. It requires a non-discontinued pharmacological treatment to prevent mood recurrences but nonadherence to medication is frequent. To this date, medication adherence in BD has been mostly evaluated in cross-sectional studies and often considered as a stable trait. We aimed to study medication adherence using a prospective person-oriented approach.
METHODS
1627 BD patients were followed on a 2 years period and assessed every 6 months. Medication adherence was evaluated at each visit with the Medication Adherence Rating Scale (MARS). A latent class mixed model (LCMM) was used to identify trajectory classes of adherence over time. Regression analyses and linear mixed model were used to search for predictors and covariables of the trajectories.
RESULTS
Three distinct and robust trajectories of medication adherence have been identified: one that starts poorly and keeps deteriorating (4.8%), one that starts poorly but improves (9%) and one that starts well and keeps improving (86.2%). A good tolerance to psychotropic medications, low depressive symptoms, the absence of comorbid eating disorders and anticonvulsant medication were associated to a better prognosis of adherence. Along the follow-up, the lower were the depressive symptoms, the better was the medication adherence (p < .001) LIMITATIONS: The use of a single measure of medication adherence although it is a validated instrument and a possible positive selection bias that might limit the generalization of our findings.
CONCLUSIONS
This study demonstrates that medication adherence in BD patients is a heterogeneous and potentially variable phenomenon.

Identifiants

pubmed: 33601722
pii: S0165-0327(20)33282-1
doi: 10.1016/j.jad.2020.12.192
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

812-819

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Julia-Lou Consoloni (JL)

Pôle de Psychiatrie, Assistance Publique Hôpitaux de Marseille, Marseille, France; Fondation FondaMental, fondation de coopération scientifique, Créteil, France.

Katia M'Bailara (K)

Fondation FondaMental, fondation de coopération scientifique, Créteil, France; Laboratoire de Psychologie EA 4139, Université de Bordeaux, Bordeaux, France; Service de Psychiatrie Adulte, Hôpital Charles-Perrens, Bordeaux, France.

Cyrille Perchec (C)

Laboratoire de Psychologie EA 4139, Université de Bordeaux, Bordeaux, France.

Bruno Aouizerate (B)

Fondation FondaMental, fondation de coopération scientifique, Créteil, France; Service de Psychiatrie Adulte, Hôpital Charles-Perrens, Bordeaux, France; Laboratoire NutriNeuro UMR 1286 INRAE, Université de Bordeaux, France.

Valérie Aubin (V)

Fondation FondaMental, fondation de coopération scientifique, Créteil, France; Pôle de Psychiatrie, Centre Hospitalier Princesse Grace, Monaco, France.

Jean-Michel Azorin (JM)

Pôle de Psychiatrie, Assistance Publique Hôpitaux de Marseille, Marseille, France; Fondation FondaMental, fondation de coopération scientifique, Créteil, France; INT-UMR7289, CNRS, Aix-Marseille Université, Marseille, France.

Frank Bellivier (F)

Fondation FondaMental, fondation de coopération scientifique, Créteil, France; AP-HP Nord, DMU Neurosciences, GHU Saint-Louis - Lariboisière - Fernand Widal, Département de Psychiatrie et de Médecine Addictologique, Paris, France; INSERM UMRS 1144, Université de Paris, Paris, France.

Nadia Correard (N)

Pôle de Psychiatrie, Assistance Publique Hôpitaux de Marseille, Marseille, France; Fondation FondaMental, fondation de coopération scientifique, Créteil, France.

Philippe Courtet (P)

Fondation FondaMental, fondation de coopération scientifique, Créteil, France; Département d'Urgence et Post Urgence Psychiatrique, CHU Montpellier, Montpellier, France; INSERM U1061, Université de Montpellier, Montpellier, France.

Caroline Dubertret (C)

Fondation FondaMental, fondation de coopération scientifique, Créteil, France; AP-HP, Département de Psychiatrie, Hôpital Louis Mourier, Colombes, France; INSERM U894, Université Paris Diderot, Sorbonne, Paris, France.

Bruno Etain (B)

Fondation FondaMental, fondation de coopération scientifique, Créteil, France; AP-HP Nord, DMU Neurosciences, GHU Saint-Louis - Lariboisière - Fernand Widal, Département de Psychiatrie et de Médecine Addictologique, Paris, France; INSERM UMRS 1144, Université de Paris, Paris, France.

Sébastien Gard (S)

Fondation FondaMental, fondation de coopération scientifique, Créteil, France; Service de Psychiatrie Adulte, Hôpital Charles-Perrens, Bordeaux, France.

Emmanuel Haffen (E)

Fondation FondaMental, fondation de coopération scientifique, Créteil, France; Département de Psychiatrie Clinique, CIC-1431 INSERM, CHU de Besançon, Besançon, France; EA481 Neurosciences, Université Bourgogne Franche-Comté, Besançon, France.

Marion Leboyer (M)

Fondation FondaMental, fondation de coopération scientifique, Créteil, France; Université Paris-Est, UMR_S955, UPEC, Inserm, U955, Equipe 15 Psychiatrie génétique, Créteil, France; AP-HP, Hôpital H. Mondor-A. Chenevier, Pôle de psychiatrie, Créteil, France.

Pierre-Michel Llorca (PM)

Fondation FondaMental, fondation de coopération scientifique, Créteil, France; Centre Hospitalier et Universitaire, Département de Psychiatrie, 63000 Clermont-Ferrand, France; Université d'Auvergne, EA 7280, 63000 Clermont-Ferrand, France.

Emilie Olié (E)

Fondation FondaMental, fondation de coopération scientifique, Créteil, France; Département d'Urgence et Post Urgence Psychiatrique, CHU Montpellier, Montpellier, France; INSERM U1061, Université de Montpellier, Montpellier, France.

Mircea Polosan (M)

Fondation FondaMental, fondation de coopération scientifique, Créteil, France; Clinique Universitaire de Psychiatrie, CHU de Grenoble et des Alpes, Grenoble, France.

Paul Roux (P)

Fondation FondaMental, fondation de coopération scientifique, Créteil, France; Service Universitaire de Psychiatrie d'Adultes et d'Addictologie, Centre Hospitalier de Versailles, 78157 Le Chesnay, France; Laboratoire HandiRESP - EA4047, UFR des Sciences de la Santé Simone Veil, Université de Versailles Saint-Quentin-En-Yvelines, France; CESP, Team "Developmental Psychiatry", Université Paris-Saclay, Inserm, 78157 Le Chesnay, France.

Raymund Schwan (R)

Fondation FondaMental, fondation de coopération scientifique, Créteil, France; Centre Hospitalier Universitaire de Nancy - Hôpitaux de Brabois, Université de Lorraine, Nancy, France.

Ludovic Samalin (L)

Fondation FondaMental, fondation de coopération scientifique, Créteil, France; Centre Hospitalier et Universitaire, Département de Psychiatrie, 63000 Clermont-Ferrand, France; Université d'Auvergne, EA 7280, 63000 Clermont-Ferrand, France.

Raoul Belzeaux (R)

Pôle de Psychiatrie, Assistance Publique Hôpitaux de Marseille, Marseille, France; Fondation FondaMental, fondation de coopération scientifique, Créteil, France; INT-UMR7289, CNRS, Aix-Marseille Université, Marseille, France. Electronic address: raoul.belzeaux@ap-hm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH